Health:Further 110 - Rich vs. Poor Lifespans, Trump’s Healthcare Shake-Up, and AI Diagnosing Your Health
Jan 4, 2025
The discussion kicks off with a look at the stock market's surprising strength amidst a struggling healthcare sector. Issues like Medicare Advantage and costly pharmacy options take center stage, highlighting the financial strain on providers. The hosts delve into the shocking reality of wealth disparities affecting lifespan, revealing that money can indeed buy health—but only to a point. Over in exciting tech, AI is stepping up as a diagnostic tool, using facial analysis to gain insights into patients' health, particularly the elderly.
AI Snips
Chapters
Transcript
Episode notes
Dealmaking Outlook
- A favorable regulatory environment under Trump could boost dealmaking.
- However, fundamental market changes and consolidation might limit deal activity's return to pre-2020 levels.
Competition and Deal Activity
- A less incumbent-friendly environment could drive deal activity by fostering competition.
- Healthcare has historically used regulations to stifle competition.
Scripta Insights Funding
- Scripta Insights raised $17 million in Series B funding, totaling $42 million.
- They help large employers navigate pharmacy benefits and secure better drug discounts.